Trial Profile
Biomarker-oriented Study of Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Tremelimumab (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
- Focus Therapeutic Use
- 23 Nov 2023 Planned End Date changed from 31 Dec 2021 to 30 Dec 2023.
- 23 Nov 2023 Status changed from completed to active, no longer recruiting.
- 06 Jun 2023 Results assessing tumor metabolic activity assessed with 18F-FDG PET is usually associated with prognosis in solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology